HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Summer Sale Get Elite for just $199.50
00
Days
00
Hours
00
Mins
00
Sec
Claim Now
Market News Market Pulse Stocks News ETF News Crypto News

Apogee Therapeutics

Contributing Author

Recent Articles by Apogee Therapeutics

May-28
Apogee Therapeutics to Participate in Upcoming June Conferences APGE APGE +5.55% GlobeNewswire
May-27
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart APGE -6.11% GlobeNewswire
May-27
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis APGE -6.11% GlobeNewswire
May-26
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026 APGE GlobeNewswire
May-11
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results APGE GlobeNewswire
Mar-26
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million APGE GlobeNewswire
Mar-24
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering APGE +7.58% GlobeNewswire
Mar-23
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering APGE +19.99% GlobeNewswire
Mar-23
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis APGE +19.99% GlobeNewswire
Mar-22
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 APGE GlobeNewswire
Mar-02
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results APGE GlobeNewswire
Feb-24
Apogee Therapeutics to Participate in Upcoming March Conferences APGE GlobeNewswire
Feb-05
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 APGE GlobeNewswire
Jan-06
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook APGE GlobeNewswire
Jan-05
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 APGE GlobeNewswire
Nov-10
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results APGE GlobeNewswire
Nov-10
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody APGE GlobeNewswire
Nov-03
Apogee Therapeutics to Participate in Upcoming Conferences APGE GlobeNewswire
Oct-10
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million APGE GlobeNewswire
Oct-08
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering APGE +12.64% GlobeNewswire
Oct-08
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering APGE +18.90% APGE +12.64% GlobeNewswire
Sep-11
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress APGE GlobeNewswire
Sep-03
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum APGE GlobeNewswire
Aug-11
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results APGE GlobeNewswire
Jul-07
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis APGE -17.32% GlobeNewswire
Jul-06
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 APGE GlobeNewswire
May-29
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference APGE GlobeNewswire
May-12
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results APGE +6.14% GlobeNewswire
May-12
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma APGE +6.14% GlobeNewswire
May-01
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference APGE GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)